Kistler-Tiffany Companies’s CRISPR Therapeutics CRSP Stock Holding History

Kistler-Tiffany Companies’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$455K	Buy	8,110 +843	+12%	+$47.8K	0.07%	208
2023 Q1	$329K	Buy	7,267 +3,050	+72%	+$148K	0.06%	235
2022 Q4	$171K	Buy	4,217 +3,435	+439%	+$182K	0.04%	290
2022 Q3	$51K	Buy	782 +266	+52%	+$19.3K	0.01%	376
2022 Q2	$31K	Sell	516 -70	-12%	-$4.12K	0.01%	437
2022 Q1	$37K	Buy	586 +205	+54%	+$12.9K	0.01%	428
2021 Q4	$29K	Buy	381 +375	+6,250%	+$32.8K	0.01%	441
2021 Q3	$1K	Hold	6	–	–	﹤0.01%	692
2021 Q2	$1K	Buy	6 +2	+50%	+$243	﹤0.01%	682
2021 Q1	$0	Hold	4	–	–	﹤0.01%	673
2020 Q4	$1K	Buy	+4	New	+$473	﹤0.01%	611

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Kistler-Tiffany Companies's CRSP Position: Q2 2023 in Review

Kistler-Tiffany Companies increased its CRISPR Therapeutics (CRSP) stake by 12% in Q2 2023, buying an estimated $47.8K and bringing the position to 8,110 shares worth $455K. The position accounts for 0.07% of the portfolio, ranked #208.

Kistler-Tiffany Companies first reported a position in CRSP in Q4 2020 and has held it in 11 quarters since. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Kistler-Tiffany Companies held 8,110 shares of CRISPR Therapeutics worth $455K as of Q2 2023.
Kistler-Tiffany Companies bought 843 CRISPR Therapeutics shares in Q2 2023, an estimated $47.8K.
CRISPR Therapeutics made up 0.07% of Kistler-Tiffany Companies's portfolio in Q2 2023, its #208 holding.
Kistler-Tiffany Companies first reported a position in CRISPR Therapeutics in Q4 2020 and has held it in 11 quarters since.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Kistler-Tiffany Companies's 13F filing for Q2 2023, filed 1 Aug 2023.